Valuation: Theraclion

Market Cap 4.46Cr 5.14Cr 4.18Cr 3.82Cr 7.21Cr 489.53Cr 7.31Cr 49Cr 19Cr 244.59Cr 19Cr 19Cr 814.09Cr P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 5.24Cr 6.04Cr 4.91Cr 4.49Cr 8.48Cr 575.73Cr 8.59Cr 57Cr 23Cr 287.65Cr 23Cr 22Cr 957.42Cr EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day+66.25%
6 months+66.25%
Current year+66.25%
Current year 0.53
Extreme 0.532
0.53
1 year 0.53
Extreme 0.532
0.53
3 years 0
Extreme 0.00017
0.59
5 years 0
Extreme 0.00017
2.28
10 years 0
Extreme 0.00017
2.6
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 01/02/2018
Director/Board Member - 13/02/2019
Director/Board Member - 13/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+66.25%-.--% - - 5.15Cr
-0.42%-0.31%+28.08%+4.21% 21TCr
-0.57%+1.18%+1.70%-22.35% 14TCr
-0.03%+6.28%-20.87%+21.31% 13TCr
+3.91%+8.02%-51.73%-2.05% 6.92TCr
+0.08%+2.47%+13.30%+11.55% 5.13TCr
-0.36%+5.11%-14.27%-19.86% 5.04TCr
-0.39%+1.14%+23.90%+10.89% 3.99TCr
-1.00%+4.03%+42.46%+36.56% 3.93TCr
+0.17%+7.59%-19.99%+20.21% 3.23TCr
Average +6.77%+3.77%+0.29%+6.72% 8.54TCr
Weighted average by Cap. +0.04%+3.04%+2.38%+3.33%

Financials

2024 2025
Net sales 8L 10L 8L 7L 13.42L 9.11Cr 13.6L 90.95L 35.69L 4.55Cr 35.92L 35.14L 15Cr 7L 8L 6L 6L 10.54L 7.16Cr 10.68L 71.42L 28.03L 3.58Cr 28.21L 27.6L 12Cr
Net income -57.57L -66.34L -53.91L -49.31L -93.1L -63Cr -94.31L -6.31Cr -2.48Cr -32Cr -2.49Cr -2.44Cr -105.09Cr -56.9L -65.57L -53.28L -48.74L -92.01L -62Cr -93.21L -6.23Cr -2.45Cr -31Cr -2.46Cr -2.41Cr -103.87Cr
Net Debt 34.11L 39.3L 31.94L 29.21L 55.15L 37Cr 55.87L 3.74Cr 1.47Cr 19Cr 1.48Cr 1.44Cr 62Cr 78.52L 90.48L 73.52L 67.26L 1.27Cr 86Cr 1.29Cr 8.6Cr 3.38Cr 43Cr 3.4Cr 3.32Cr 143.34Cr
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36

Annual profits - Rate of surprise